Labcorp (LH)
(Delayed Data from NYSE)
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$216.00 USD
+0.93 (0.43%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research
by Zacks Equity Research
PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.
Are Investors Undervaluing These Medical Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Exact Sciences' (EXAS) Oncotype DX Test Study Data Favorable
by Zacks Equity Research
Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.
LH vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. WST: Which Stock Is the Better Value Option?
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN) on strong third-quarter results and raised 2021 guidance.
Here's Why You Should Invest in AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.
Here's Why You Should Retain Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.
CVS Health (CVS) New Alliance to Boost Digital Transformation
by Zacks Equity Research
CVS Health's (CVS) collaboration with Microsoft will accelerate digital transformation and empower employees to provide more customized and affordable care.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on strong third-quarter 2021 results and raised full-year outlook.
Thermo Fisher (TMO) Launches K-12 COVID-19 Test in Texas Schools
by Zacks Equity Research
Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
Cooper Companies (COO) Q4 Earnings Lag Estimates, Margins Up
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results reflect solid segmental and geographical performances.
Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases
by Zacks Equity Research
Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Quest Diagnostics (DGX) Expands Testing Suite With NGS Test
by Zacks Equity Research
Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.
Here's Why You Should Invest in NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR.
Walgreens (WBA) Buys Remaining Stake in German Wholesale Business
by Zacks Equity Research
Walgreens' (WBA) recent acquisition of the remaining ownership stake helps the company to further solidify its position as a leading pharmaceutical wholesaler in Germany.
Masimo's (MASI) Rad-G Clinical Study Trial Outcome Favorable
by Zacks Equity Research
Masimo's (MASI) latest study results demonstrate that Rad-G Pulse Oximeter can help detect pediatric pneumonia.
SeaSpine (SPNE) Enhances ACDF Procedure With Admiral ACP System
by Zacks Equity Research
SeaSpine's (SPNE) next-generation Admiral ACP System covers the largest segment in the estimated $1.30-billion cervical spine surgery market.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) on strong fiscal fourth-quarter results and progress in digital health.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) owing to strong third-quarter results and bullish 2021 outlook.
Bio Rad (BIO) Grows Internationally on New Product Launches
by Zacks Equity Research
Strength in Bio Rad's (BIO) key product lines across major geographic regions buoys optimism.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) on strength in its key product lines and raised 2021 guidance.
CVS Health (CVS) Installs Time-Delay Safes in Texas Pharmacies
by Zacks Equity Research
CVS Health's (CVS) time-delay safes reduce theft and diversion of opioid medications and boost the security of stores, creating a safe environment for patients and staff.